New drug combo trial offers hope for advanced lung cancer patients

NCT ID NCT06516887

First seen Apr 21, 2026 · Last updated Apr 21, 2026

Summary

This study is testing whether combining two experimental drugs (bemcentinib and pacritinib) is safe and effective for people with advanced lung adenocarcinoma who have already tried other treatments. Researchers will give the drug combination to about 44 participants and measure how well it controls the cancer and extends life. The goal is to see if this combination can better manage the disease when standard treatments have stopped working.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Texas Health Science Center at San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.